[Lipoprotein(a): relationships with atherosclerosis and valvular heart disease, and emerging therapies]. / Lipoproteina(a): associazione con la malattia aterosclerotica e valvolare e terapie emergenti.
G Ital Cardiol (Rome)
; 25(2): 76-87, 2024 02.
Article
em It
| MEDLINE
| ID: mdl-38270363
ABSTRACT
Lipoprotein(a) [Lp(a)] is a well-established cardiovascular risk factor, whose relationship with atherosclerotic disease has been confirmed by epidemiological, genome-wide association, Mendelian randomization, and meta-analysis studies. This association is determined by its pro-atherogenic, pro-thrombotic and pro-inflammatory properties. Lp(a) is the most common monogenic risk factor for atherosclerosis, with a prevalence of about 1 in 5 people. Recently, its etiopathogenetic relationship with calcific and degenerative valvular heart diseases, particularly with aortic and mitral stenosis, has been suspected. It has not yet been demonstrated whether its reduction translates into a lower risk of cardiovascular events. Up to now, Lp(a) has been considered a non-modifiable risk factor, as current lipid-lowering drugs have limited effects on its levels. New specific lipid-lowering therapies with high efficacy in reducing circulating Lp(a) levels are being investigated in randomized trials; however, the effects of this reduction on cardiovascular outcomes are still being studied.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aterosclerose
/
Doenças das Valvas Cardíacas
/
Estenose da Valva Mitral
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
It
Revista:
G Ital Cardiol (Rome)
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article